Molecular Biosystems, Mallinckrodt Group Inc. deal

The companies amended their 1988 agreement, entering into a new distribution and funding agreement for MB's Albunex contrast agent for ultrasound imaging, and for FS069, another MB contrast agent.

Under the new agreement, Mallinckrodt will purchase $13 million of the San Diego company's common stock at $11.62 per share, giving Mallinckrodt 10 percent ownership in MB. Mallinckrodt also will pay an additional $20 million over four years to support FS069 clinical trials and associated product development. ...